Article Information
History
- March 15, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Robyn M. Barfield1,
- Yun Cheol Kim1,
- Stepan Chuprakov1,
- Fangjiu Zhang1,
- Maxine Bauzon1,
- Ayodele O. Ogunkoya1,
- Dominick Yeo1,
- Colin Hickle1,
- Mark D. Pegram2,
- David Rabuka1 and
- Penelope M. Drake1,*
- 1Catalent Biologics, 5959 Horton Street, Ste. 400, Emeryville, CA 94608, USA
- 2Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA
- ↵*Corresponding author: Penelope Drake, Catalent Biologics, 5959 Horton Street, Ste. 400, Emeryville, CA 94608; Email: penelope.drake{at}catalent.com.
Posted March 15, 2020.
A novel HER2-targeted antibody-drug conjugate offers the possibility of clinical dosing at trastuzumab-equivalent exposure levels
